Radar · Infectious Diseases in United Kingdom
Best Infectious Diseases Companies in United Kingdom
The 148 best Infectious Diseases companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunocore.
By Riya SenguptaFinancials
148companies tracked
$2.3Bdisclosed funding
0unicorns
82have raised
Ranked by disclosed equity funding and recent momentum, this directory covers 148 Infectious Diseases companies operating in the United Kingdom, collectively holding $2.3B in tracked funding. That's a real number. No unicorns in the cohort, which tells you something about where this sector sits: capital is present, but the big exits haven't landed yet. F2g leads the field at $353M raised, and Vicebio follows at $100M, with the rest of the pack clustered well below that. Centauri Therapeutics at $65M is the next name worth watching. Investors like Future Planet Capital, Morningside, and UKRI are the ones writing cheques here, and their presence signals long-horizon conviction rather than quick-flip thinking.
Hot themes driving coverage right now include neglected tropical diseases, malaria incidence, and gene therapy for rare diseases, which is where a lot of the international disease burden argument gets made, as recent commentary on infectious disease innovation makes clear. I'd flag that the regulatory path for gene therapy alone adds years and cost that funding totals don't always reflect. So if you're mapping this space, don't let the gap between F2g's $353M and iFAST Diagnostics' $9M fool you into thinking the middle of the market is thin. It's fragmented, early, and moving.
FLIAR INTELLIGENCE · INFECTIOUS DISEASES × UNITED KINGDOM
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
59%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2014median founding year
121kcombined LinkedIn audience
56%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Infectious Diseases companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunocore Developer of bispecific T cell receptor therapies for human diseases | $525M | 47 mo ago | 293 293 → 604 (+106%) · sector median +10% | Nicholas Cross Co-Founder | 3 signals ▼67% Earnings | 776 patents Patents concentrated in chemistry & materials | 3 job openings · 1 launch |
| 2 | F2g Developer of therapeutic treatments for rare and life threatening infections 64Fin. health top 22%Funding top 23%Moat top 26%Growth top 28% All 11 signals ▾Fin. healthtop 22% Fundingtop 23% Moattop 26% Growthtop 28% Patentstop 38% Markettop 45% Innovationtop 46% Talentbottom 49% Globalbottom 47% Techbottom 28% Newsbottom 22% Fin. health: Revenue ~$101M Funding: Raised $353M across 12 rounds · 12 rounds over 24 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $353M | 21 mo ago | 27 | Francesco Lavino CEO | — | 142 patents Antifungal heterocyclic drug compounds and their pharmaceutical formulations. | — |
| 3 | Pulmocide Developer of inhaled antifungal medicines for treating respiratory lung infections | $205M | 42 mo ago | 9 | Pete Strong Co-Founder | — | 124 patents Polymorph forms and manufacturing processes for triazole antifungal agents | — |
| 4 | ReViral Developer of antiviral compounds for RSV | $121M | 69 mo ago | 28 | Khattereh Ahmadi Co-Founder | — | 91 patents Antiviral benzodiazepine derivatives for treating respiratory syncytial virus infections | — |
| 5 | Vicebio Developer of vaccines to treat viral infectious diseases 35Growth top 15%Funding top 26%News top 26%Moat top 47% All 9 signals ▾Growthtop 15% Fundingtop 26% Newstop 26% Moattop 47% Talentbottom 49% Globalbottom 37% Patentsbottom 35% Marketbottom 25% Innovationbottom 22% Growth: Fresh capital in last 24 mo Funding: Raised $100M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $100M | 20 mo ago | 4 | Emmanuel Hanon CEO | 6 signals ▲500% M&A | 2 patents Recombinant chimeric fusion protein vaccines for hMPV and RSV respiratory viruses | — |
| 6 | Chimerix Developer of antiviral oral therapeutics | $95M | 139 mo ago | 78 | — | — | — | — |
| 7 | Oxford Immunotec Commercial-stage diagnostics company using immune markers to diagnose disease | $94M | 101 mo ago | 184 | — | — | 40 patents Immunodiagnostic assays for TB, SARS‑CoV‑2 and microbial protein‑fragment ELISpot testing | — |
| 8 | DNA Electronics Developer of semiconductor‑based DNA‑sequencing systems for use in healthcare | $90M | 116 mo ago | 111 111 → 174 (+57%) · sector median +10% | Christofer Toumazou Founder & Executive Chairman | — | 123 patents Patents concentrated in chemistry & materials | — |
| 9 | Sense Biodetection Provider of point of care molecular diagnostics solutions | $79M | 55 mo ago | 43 | — | — | 82 patents Rapid nucleic acid detection biosensors with integrated heating for point‑of‑care diagnostics | — |
| 10 | Centauri Therapeutics Developer of immunotherapeutics to treat infectious diseases 35Funding top 26%Growth top 35%Moat top 36%Patents top 46% All 9 signals ▾Fundingtop 26% Growthtop 35% Moattop 36% Patentstop 46% Talentbottom 49% Innovationbottom 42% Globalbottom 42% Techbottom 41% Marketbottom 25% Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $65M | 3 mo ago | 6 | Jennifer Schneider CEO | — | 50 patents Patents concentrated in chemistry & materials | — |
| 11 | Prokarium Developer of bacterial immunotherapy treatments for various types of cancer | $62M | 41 mo ago | 20 20 → 17 (-15%) · sector median +10% | Ibraheem Mahmood CEO | — | 77 patents Patents concentrated in health & consumer products | — |
| 12 | QuantuMDx Group Manufacturer of molecular diagnostic platforms and assays for infectious diseases | $57M | 46 mo ago | 98 98 → 53 (-46%) · sector median +10% | Jonathan Halloran CEO & ex-Co-Founder | — | 154 patents Microfluidic nucleic‑acid diagnostic platforms for rapid qPCR and sample‑prep automation | — |
| 13 | SpyBiotech Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology | $39M | 39 mo ago | 10 10 → 20 (+100%) · sector median +10% | Simon Draper Co-Founder | — | 29 patents Engineering adenoviral vectors and capsid-modified viral vaccines for immunization | — |
| 14 | PrEP Biopharm Developing RNA based immunomodulators for the prevention of respiratory infections | $32M | 127 mo ago | 118 | — | — | — | — |
| 15 | Emergex Vaccines Developer T-cell Vaccines for treating viral and bacterial infections | $30M | 51 mo ago | 19 | Storme Moore-Thornicroft Co-Founder | — | 89 patents Peptide-based vaccines and MHC I epitope therapeutics for coronaviruses and flaviviruses | — |
| 16 | Novacta Biosystems Antibiotics developer | $29M | 203 mo ago | 51 | — | — | 139 patents Novel lantibiotic and polymyxin antibiotic compounds and their infusion formulations | — |
| 17 | Immune Targeting Systems Vaccines against mutating viruses | $20M | 195 mo ago | 46 | — | — | 36 patents Fluorocarbon‑conjugated peptide vaccine delivery platforms for infectious and oncology antigens | — |
| 18 | Phico Therapeutics Developer of antibiotic technology to address multi-drug resistant infections | $20M | 61 mo ago | 16 | — | — | 101 patents Engineered bacteriophages with customized tail fibers for targeted antibacterial therapy | — |
| 19 | Base Immune Developer of AI based vaccines for treating infectious diseases | $20M | 27 mo ago | 8 | Joshua Blight Co-Founder | — | — | — |
| 20 | Population Genetics Developing and out-licensing biochemical tools and approaches for NGS applications | $18M | 175 mo ago | 5 | Sam Eletr Co-Founder & Chairman | — | 116 patents Advanced DNA sequencing library prep, normalization, and high‑sensitivity variant detection | — |
| 21 | Aquapharm Marine-based antibiotics developer | $16M | 194 mo ago | — | Simon Best CEO | — | — | — |
| 22 | NovaBiotics Developer of therapeutics for infectious diseases | $13M | 88 mo ago | 13 13 → 15 (+15%) · sector median +10% | — | — | 360 patents Cysteamine-based pharmaceutical formulations for antiviral and lung disease therapies | — |
| 23 | NeuTec Pharma Developer of recombinant antibody therapies for infectious diseases | $12M | 337 mo ago | 20 | Ruth Christine Matthews Founder & COO | — | 105 patents HSP90‑targeted therapeutics and antibody treatments for fungal, bacterial, and cancer diseases | — |
| 24 | MGB Biopharma Developer of drugs for drug-resistant bacterial infections | $12M | 81 mo ago | 3 | Raymond Spencer Founder | — | — | — |
| 25 | ProteinLogic Biomarker discovery and exploitation platform | $11M | 28 mo ago | — | Nicolas Huber CEO | — | 14 patents Discovery and application of protein biomarkers for disease diagnosis, notably tuberculosis. | — |
| 26 | EpilepsyGTx Developer of gene therapies for focal refractory epilepsy 13News top 38%Funding top 40%Partners top 45%Talent bottom 49% All 7 signals ▾Newstop 38% Fundingtop 40% Partnerstop 45% Talentbottom 49% Globalbottom 36% Techbottom 30% Marketbottom 25% News: 3 BI events in 12 mo (of 5 tracked, 1 types) · Top themes: Funding Funding: Raised $10.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 13/100 | $10M | 6 mo ago | — | Nicolas Koebel CEO | 3 signals Funding | — | — |
| 27 | Genedrive Provider of point of care molecular diagnostics platform for genotyping and sequence analysis | $9M | 14 mo ago | 43 43 → 45 (+5%) · sector median +10% | Christopher Potten Co-Founder | — | — | 1 partnership |
| 28 | Poolbeg Pharma Developer of therapeutics for the treatment of infectious diseases | $9M | 12 mo ago | 7 | Carol Dalton Co-Founder | — | 18 patents p38 MAPK inhibitor therapeutics for cytokine storm mitigation in influenza and cancer immunotherapy | — |
| 29 | iFAST Diagnostics Standalone pathology laboratory center 40News top 24%Growth top 25%Talent top 33%Funding top 47% All 9 signals ▾Newstop 24% Growthtop 25% Talenttop 33% Fundingtop 47% Techbottom 48% Productbottom 39% Innovationbottom 37% Globalbottom 37% Marketbottom 17% News: 10 BI events in 12 mo (of 26 tracked, 5 types) · +233% YoY Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $9M | 0 mo ago | 6 | Hywel Morgan Co-Founder & CTO | 10 signals ▲233% Earnings · Leadership | — | 1 partnership · 2 awards |
| 30 | iosBio Developer of therapeutic solutions for treating diseases like Covid-19, Influenza & others | $8M | 51 mo ago | 15 | — | — | 15 patents Engineering chimeric coronavirus spike proteins to increase viral titers for vaccine production | — |
| 31 | Destiny Pharma Developer of drugs for the treatment of infectious diseases | $7M | 47 mo ago | 23 | William Love Founder | — | 62 patents Antimicrobial agents targeting bacterial biofilms and prophylactic infection treatments | — |
| 32 | PBD Biotech Developer of diagnostic test to detect Mycobacterium in bovines | $6M | 44 mo ago | 5 | — | — | 14 patents TB diagnostics and therapeutics, especially bacteriophage-based mycobacterial detection methods. | — |
| 33 | Infex Therapeutics Developer of drugs for treating multiple infectious diseases 37Patents top 27%Innovation top 33%Funding top 44%Moat top 45% All 8 signals ▾Patentstop 27% Innovationtop 33% Fundingtop 44% Moattop 45% Talentbottom 49% Globalbottom 44% Techbottom 37% Marketbottom 32% Patents: 60 patents matched (strict assignee match) · 50 filings since 2022 vs 10 in 2017-21 Innovation: 60 patents (top 42% of patent-holders) · 50 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $6M | 1 mo ago | 23 23 → 24 (+4%) · sector median +10% | Pete Jackson CEO | — | 60 patents Small-molecule antivirals and metallo‑beta‑lactamase inhibitors for infectious diseases | — |
| 34 | Chain Biotech Developer of microbiome-based oral immunotherapies | $6M | 36 mo ago | 8 | — | — | — | — |
| 35 | Momentum Bioscience Developer of diagnostic solutions for the detection of infectious diseases | $6M | 57 mo ago | 13 | — | — | 67 patents Rapid microbial detection, separation, and enumeration technologies for diagnostics and food safety | — |
| 36 | Glox Theraputics Developer of precision antibiotics to target antimicrobial resistant pathogens | $5M | 19 mo ago | — | Colin Kleanthous Co-Founder | — | — | 1 award |
| 37 | SMi Developer of a single molecule imaging tool for research and clinical diagnostics | $5M | 36 mo ago | 15 | Andrew Thompson Founder & Director | — | — | 1 partnership |
| 38 | Linear Diagnostics Developer of a molecular diagnostic test for sexually transmitted infections | $4M | 36 mo ago | 4 | Matthew Hicks Founder & CTO | — | — | — |
| 39 | Nemesis Bioscience Developer of therapeutics to reverse microbial resistance to antibiotics | $3M | 50 mo ago | 8 | Frank Massam Founder & CEO | — | 24 patents Nucleic acid delivery vectors and therapeutic formulation technologies for gene‑based medicines. | — |
| 40 | ReadyGo Provider of diagnostic test and sample collection tools for research labs | $3M | 15 mo ago | 8 | Elaine Warburton Co-Founder | — | — | — |
| 41 | Aptorum Group Developer of small molecular therapeutics for multiple disorders | $3M | 42 mo ago | 26 | Ian Huen Founder & CEO | 5 signals Leadership · M&A | — | — |
| 42 | Fuse Provider of ultra rapid diagnostics solutions for the detection of COVID-19 | $2M | 24 mo ago | — | Harry Lamble CEO | — | — | — |
| 43 | Presymptom Health Developer of AI-based diagnostic blood tests for infection. | $2M | 15 mo ago | 3 | Iain Miller Chief Executive Officer | — | — | — |
| 44 | Halo Therapeutics Developer of therapeutics for the treatment of Covid-19 | $2M | 37 mo ago | 1 | Daniel Fitzgerald Co-Founder & CEO | — | — | — |
| 45 | Amprologix Developer of antimicrobial-resistant drugs | $993K | 8 mo ago | — | Mat Upton Founder & CSO | — | 2 patents Design and synthesis of novel antimicrobial peptide therapeutics | — |
| 46 | Luas Diagnostics Developer of sensors and connected app for diabetes management | $949K | 38 mo ago | 3 | — | — | — | — |
| 47 | Biomarx Developer of automated diagnostic systems for molecular testing at point of care 24Funding top 46%Talent bottom 49%Global bottom 33% All 3 signals ▾Fundingtop 46% Talentbottom 49% Globalbottom 33% Funding: Raised $942k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $942K | 5 mo ago | — | Sean Macfarlane Founder | — | — | — |
| 48 | Evolvere BioSciences Developer of next generation antibiotics using artificial intelligence models to outpace bacterial resistance | $500K | 24 mo ago | — | Weronika Ślesak Co-Founder | — | — | — |
| 49 | GenomeKey Developer of diagnostic solutions for infectious diseases by using DNA sequencing and machine learning | $259K | 22 mo ago | 10 | Michael Roberts Co-Founder & CEO | — | — | — |
| 50 | Renewvax Developer of vaccines to treat bacterial infections and antimicrobial resistance | $166K | 10 mo ago | 6 | Aras Kadioglu Co-Founder | — | — | — |
Top 12 Infectious Diseases companies in United Kingdom
#1
Series A · Kent, England · founded 2014 · 6 employees$64.9Mraised▾
Series A · Kent, England · founded 2014 · 6 employees
Developer of immunotherapeutics to treat infectious diseases. The company has proprietary Alphamer technology based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Growth
top 35%Moat
top 36%Patents
top 46%Talent
bottom 49%Innovation
bottom 42%Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) · Last round Series A (Feb 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 50 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers — 2.3% of this cohort's audience
Funding rounds
- Feb 2026Series A$8.1M
- Jul 2025Grant (prize money)$5.1M
- Nov 2024Grant (prize money)$1.3M
- Jul 2023Series A$11.5M
Founders & team
Investors
Kent County Council, EJ Capital, Wren Capital, Discovery Park, Renaissance Capital Partners, Animatrix Capital Llp
Tech stack
CookiebotGodaddyGoogle AnalyticsHstsJqueryMicrosoft 365
#2
Seed · Southampton, England · founded 2022 · 6 employees$8.9Mraised▾
Seed · Southampton, England · founded 2022 · 6 employees
Standalone pathology laboratory center
Fliar Intelligence Index™ 40how this company ranks against its industry peers
News
top 24%Growth
top 25%Talent
top 33%Funding
top 47%Tech
bottom 48%Product
bottom 39%News: 10 BI events in 12 mo (of 26 tracked, 5 types) · +233% YoY · Top themes: Earnings, Leadership
Growth: Fresh capital in last 24 mo
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated · 2 leadership moves in 12 mo
Audience (LinkedIn): 3k LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 2 awards (incl. iFAST Diagnostics) announced in 12 mo
Funding rounds
- Nov 2024Seed$6.4M
- Jan 2023Seed$2.4M
Founders & team
Investors
E Ink, Raw Ventures, OKG Capital, QantX, UK Innovation Science & Seed Fund, Kadmos Capital
Tech stack
AstraCloudflareCloudflare Bot ManagementCore-JsElementorGodaddy
#3
Series A · Alderley Edge, England · founded 2016 · 23 employees$5.9Mraised▾
Series A · Alderley Edge, England · founded 2016 · 23 employees
Developer of drugs for treating multiple infectious diseases. The company's proprietary platform has developed RESP-X for treating respiratory infections in patients with lungs damaged, MET-X helps to treat urinary tract infections caused by critical priority pathogens, GON-X for gonorrhea, VAP-X helps in the prevention & treatment of hospital-lung infections, and many more.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Patents
top 27%Innovation
top 33%Funding
top 44%Moat
top 45%Talent
bottom 49%Global
bottom 44%Patents: 60 patents matched (strict assignee match) · 50 filings since 2022 vs 10 in 2017-21 · Latest publication 2026
Innovation: 60 patents (top 42% of patent-holders) · 50 filings since 2022 vs 10 in 2017-21
Funding: Raised $5.9M across 3 rounds · 3 rounds over 9 yrs (0.3/yr) · Last round Series A (May 2026)
Audience (LinkedIn): 3k LinkedIn followers — 2.2% of this cohort's audience
Funding rounds
- May 2026Series A$5.9M
- Mar 2019Seed$3M
- 2017Seed$2.9M
Founders & team
Investors
LifeArc, Bruntwood, Mahanagar Gas, The GM&C Life Sciences Fund, Catapult Ventures, Gooddies
#4
Series H · Manchester, England · founded 1998 · 27 employees$353.3Mraised▾
Series H · Manchester, England · founded 1998 · 27 employees
Developer of therapeutic treatments for rare and life threatening infections. Research focuses on identifying and creating pharmaceutical compounds to address fungal pathogens. These medical products aim to provide treatment options for patients affected by serious fungal conditions.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Fin. health
top 22%Funding
top 23%Moat
top 26%Growth
top 28%Patents
top 38%Market
top 45%Fin. health: Revenue ~$101M
Funding: Raised $353M across 12 rounds · 12 rounds over 24 yrs (0.5/yr) · Last round Series H (Sep 2024)
Moat: Editorial + unicorn rating 8/10 · IP moat: 142 patents · Soonicorn
Audience (LinkedIn): 8k LinkedIn followers — 6.6% of this cohort's audience
Funding rounds
- Sep 2024Series H$100M
- Aug 2022Series E$70M
- Aug 2020Series D$60.8M
- Jan 2019Series C—
Founders & team
Investors
Morningside, European Investment Bank, Merifin Capital, Astellas Venture Management, BankInvest, K Nominees
Tech stack
AstraCookieyesCore-JsElementorGoogle Font ApiJquery
#5
Series A · Waterbeach, Cambridgeshire · founded 2021$10Mraised▾
Series A · Waterbeach, Cambridgeshire · founded 2021
Developer of gene therapies for focal refractory epilepsy. It offers gene therapy program EPY201 which uses an AAV9 capsid, an engineered Kv1.1 potassium channel and a CAMK2A promoter. It is delivered directly to the target seizure focus by intraparenchymal administration.
Fliar Intelligence Index™ 13how this company ranks against its industry peers
News
top 38%Funding
top 40%Partners
top 45%Talent
bottom 49%Global
bottom 36%Tech
bottom 30%News: 3 BI events in 12 mo (of 5 tracked, 1 types) · Top themes: Funding
Funding: Raised $10.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Dec 2025)
Partners: 1 partnership announcement in 12 mo (1 in 24 mo)
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- Dec 2025Series A$33M
- Jun 2024Seed$10M
Founders & team
Investors
UCL Technology Fund, HTH, XGEN Venture, British Business Bank
Tech stack
Apache Http ServerGodaddyGoogle AnalyticsGoogle Font ApiHstsJquery
#6
Acquired · London, England · founded 2019 · 4 employees$100Mraised▾
Acquired · London, England · founded 2019 · 4 employees
Developer of vaccines to treat viral infectious diseases. The company has Molecular Clamp technology for high yield production of viral fusion proteins in native trimeric “prefusion” form. The lead candidate of the company includes VXB-211 which targets respiratory syncytial virus (RSV). The company has developed a pipeline for Metapneumovirus, influenza, and SARS-CoV-2.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Growth
top 15%Funding
top 26%News
top 26%Moat
top 47%Talent
bottom 49%Global
bottom 37%Growth: Fresh capital in last 24 mo
Funding: Raised $100M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Series B (Sep 2024)
News: 6 BI events in 12 mo (of 7 tracked, 2 types) · +500% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding rounds
- Sep 2024Series B$100M
Founders & team
Investors
TCG Crossover, Avoro Capital, VenBio, UniQuest, Medicxi
#7
Public · London, England · founded 2021 · 7 employees$8.9Mraised▾
Public · London, England · founded 2021 · 7 employees
Developer of therapeutics for the treatment of infectious diseases. The company's product pipeline include POLB 001 is a p38 MAP Kinase inhibitor and small molecule immunomodulator that reduces harmful inflammation in patients with influenza, POLB 002 for respiratory virus infections treatment and POLB 003 is a Melioidosis vaccine.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 3.3% of this cohort's audience
Funding rounds
- May 2025Post IPO$6.5M
- Nov 2022Grant (prize money)$2.4M
Founders & team
Investors
Department of Enterprise, Trade and Employment
Tech stack
Amazon AlbAmazon SesAmazon Web ServicesCloudflareCloudflare Bot ManagementCore-Js
#8
Seed · Belfast, Northern Ireland · founded 2025$941.9Kraised▾
Seed · Belfast, Northern Ireland · founded 2025
Developer of automated diagnostic systems for molecular testing at point of care. The company provides a system that streamlines the diagnostic workflow. It offers a platform combining single-use cartridges with screen-printed electrodes. The system aims to decentralise diagnostic services and expand patient access to testing.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 46%Talent
bottom 49%Global
bottom 33%Funding: Raised $942k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Single-market focus (United Kingdom)
Audience (LinkedIn): 265 LinkedIn followers
Funding rounds
- Jan 2026Grant (prize money)—
- Jan 2026Seed$941.9K
Founders & team
Investors
SFC Capital, Clarendon Fund Managers, University of Strathclyde, IntertradeIreland, Techstart
#9
Public · Manchester, England · founded 2000 · 43 employees$9.3Mraised▾
Public · Manchester, England · founded 2000 · 43 employees
Provider of point of care molecular diagnostics platform for genotyping and sequence analysis. The company offers MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, and Genedrive HCV ID Kit is used to screen for hepatitis C and COVID-19.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers — 4.9% of this cohort's audience
Activity: 1 partnerships (incl. Thermo Fisher Scientific) announced in 12 mo
Funding rounds
- Apr 2025Post IPO$1.6M
- Nov 2018Post IPO$7.7M
Founders & team
Investors
Calculus Capital, Global Health Investment Fund
#10
Public · Abingdon, England · founded 2008 · 293 employees$525Mraised▾
Public · Abingdon, England · founded 2008 · 293 employees
Developer of bispecific T cell receptor therapies for human diseases. These biological medicines utilize modular technology to modulate immune system activity. The therapies target diseased cells to facilitate destruction or reduce immune responses in patients with cancer, infectious diseases, and autoimmune conditions. The research and development process focuses on creating treatments that interact with the human leukocyte antigen system to address unmet medical needs.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 48k LinkedIn followers — 39.9% of this cohort's audience
Hiring: 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Clinical Supply Chain Program Lead, Associate Director, Product Marketing (US)
Activity: 1 product launches announced in 12 mo
Funding rounds
- Jul 2022Post IPO$140M
- Feb 2021Post IPO$15M
- Jan 2021Series C$75M
- Jan 2021Conventional Debt$100M
Founders & team
Investors
BlackRock, Oxford Finance, Gates, Lilly, Woodford Investment Management, RTW Investments
Tech stack
Amazon CloudfrontAmazon Web ServicesApache Http ServerApple Icloud MailBootstrapDatatables
#11
Seed · Plymouth, England · founded 2018$993Kraised▾
Seed · Plymouth, England · founded 2018
Developer of antimicrobial-resistant drugs. The lead candidate NI01, is a bactericidal peptide for topical use for nasal decolonization of methicillin-resistant Staphylococcus aureus, pneumonia, and surface skin infections such as impetigo.
Funding rounds
- Oct 2025Seed$993K
Founders & team
#12
Seed · Bath, England · founded 2020 · 8 employees$3.2Mraised▾
Seed · Bath, England · founded 2020 · 8 employees
Provider of diagnostic test and sample collection tools for research labs. The company offers a sample collection product called "Snap" and a diagnostic testing product called "Snapshot". Also, offers a rapid test platform for small laboratories, pharmacies, and off-grid diagnostic requirements.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Mar 2025Seed$644.5K
- Jul 2022Seed$1.8M
- Feb 2022Seed$297.4K
- Mar 2021Seed$1.2M
Founders & team
Investors
British Business Bank, Foresight Group
Funding & investor landscape
$2.3Btotal disclosed funding
74companies funded
260disclosed rounds
1rounds last 90 days
Most active investors
Gov11 rounds
Notable founders
Jennifer Schneider
CEO · Centauri Therapeutics
Hywel Morgan
Co-Founder & CTO · iFAST Diagnostics
Toby King
CEO · iFAST Diagnostics
Pete Jackson
CEO · Infex Therapeutics
Francesco Lavino
CEO · F2g
Nicolas Koebel
CEO · EpilepsyGTx
Emmanuel Hanon
CEO · Vicebio
Carol Dalton
Co-Founder · Poolbeg Pharma
Cathal Friel
Chairman and Co-Founder · Poolbeg Pharma
Sean Macfarlane
Founder · Biomarx
Christopher Potten
Co-Founder · Genedrive
Catherine Booth
Co-Founder · Genedrive
Prism market signals · United Kingdom · country-scoped Prism corpus, 1,876,359 docs
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United Kingdom
How research on Diagnostics is moving in the United Kingdom
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,703 United Kingdom-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 28% → 48% across 2008–2026.
top research entities
- London School of Hygiene & Tropical Medicine369
- Imperial College London228
- University of Oxford223
- University College London133
- Liverpool School of Tropical Medicine103
leading researchers
Christopher P. Price · Emma M. Harding‐Esch · Rosanna Ŵ. Peeling · Moniek Bresser · Kwame Shanaube · Musonda Simwinga · R.M. Erhardt · P.A. Mahlatsi
▲
Breakthroughs326 · 12%
▲ 7%→15% share
▲2.1× share momentum2 median citations58% since 2021mostly methods-led
Liquid biopsy breakthroughs are surging — UK papers quadrupled from 9 to 39, with Biomarker topics rising 10-fold.
rising sub-themes (early→recent)
- Liquid biopsy9→39
- Point-of-care testing21→45
- Biomarker2→21
- Computational biology4→19
- Cancer7→21
Newly emergingCoronavirus disease 2019 (COVID-19) 0→12 · DNA sequencing 0→11 · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→10
Landmark The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an A · 640 cites
◆
Advancements1,157 · 43%
▲ 42%→44% share
▲1.0× share momentum2 median citations49% since 2021mostly empirical
Liquid biopsy advancements intensifying — papers jumped 32 to 138, while Cancer and Biomarker advancements tripled simultaneously.
rising sub-themes (early→recent)
- Liquid biopsy32→138
- Biopsy8→56
- Cancer14→53
- Biomarker5→41
- Point-of-care testing128→159
Newly emergingCoronavirus disease 2019 (COVID-19) 0→20 · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→15 · Receiver operating characteristic 0→11
Landmark T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation · 303 cites
▼
Concerns924 · 34%
▼ 39%→29% share
▼0.7× share momentum6 median citations41% since 2021mostly empirical
Pandemic-linked concerns newly emerged — SARS-CoV-2, COVID-19, and Pandemic together added 44 concern papers from zero.
rising sub-themes (early→recent)
- Liquid biopsy22→52
- Biopsy6→22
- Health care12→25
- Qualitative research2→14
- Diagnostic test33→44
Newly emergingSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→16 · Coronavirus disease 2019 (COVID-19) 0→15 · Pandemic 0→13
Landmark Paper-based microfluidic point-of-care diagnostic devices · 1,866 cites
RESEARCH HOTSPOTS · United Kingdom
Where diagnostics is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
London875 · +0.21
Oxford410 · +0.18
Manchester102 · +0.31
Edinburgh63 · +0.18
Bristol60 · +0.20
Cambridge59 · +0.31
Glasgow56 · +0.51
Birmingham35 · +0.26
PATENT SIGNAL · United Kingdom
Who's filing diagnostics patents in the United Kingdom
United Kingdom diagnostics patent filing is steady — 9 filings from 10 assignees (2021–2025), led by Oxford Cancer Analytics Oxcan, French IAN, Koninkl Philips Electronics; annual filings 1→1.
9 filings10 assigneespeak 5/yr2021–2025
filing momentum (YoY 2021–2025)
top patent filers
- Oxford Cancer Analytics Oxcan4
- French IAN3
- Koninkl Philips Electronics3
- Oxford Cancer Analytics3
- Young Nigel D2
- VAN DER ZAAG Pieter J2
- Biomavericks1
- DNAE Group Holdings1
Common questions
How many Infectious Diseases companies are there in United Kingdom?
Radar tracks 148 indexable Infectious Diseases companies headquartered in United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Infectious Diseases companies in United Kingdom?
The Infectious Diseases companies in United Kingdom on this list have raised a combined $2.3B in disclosed equity funding across 74 funded companies.
Which is the highest-funded Infectious Diseases company in United Kingdom?
Immunocore is the highest-funded Infectious Diseases company in United Kingdom, with $525M in disclosed equity funding.
How many Infectious Diseases companies in United Kingdom are funded?
74 of the 148 Infectious Diseases companies in United Kingdom on this list have disclosed at least one equity funding round.
How many Infectious Diseases unicorns are there in United Kingdom?
None of the Infectious Diseases companies in United Kingdom on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in United Kingdom Infectious Diseases companies?
The most active investors in United Kingdom Infectious Diseases companies on this list include Gov, Future Planet Capital, Morningside, UK Innovation Science & Seed Fund, Ukri.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.